title: A decade of follow-up and therapeutic drug monitoring in HIV-2 immunocompromised patients at St Camille and General Lamizana Military Medical Centers, Burkina Faso, West Africa.
abstract: Although, HIV-2 is generally less pathogenic than HIV-1 and its progression towards AIDS occurs less frequently. HIV-2 remains an important cause of disease in West Africa. This study aimed to evaluate HIV-1 and HIV-2 prevalence among pregnant women and to describe the demographic and clinical profile of patients with HIV-2 infection from 2003-2013 at St Camille and General Lamizana Military Medical Centers. A retrospective investigation was conducted using 12,287 medical records from patients screened for HIV. To respond to the lack of data available regarding HIV-2 treatment and also to address the approach to clinical, biological as well as therapeutic monitoring, 62 HIV-2 infected patients' medical records were studied. Seroprevalence of 10.6 and 0.14% were obtained, respectively for HIV-1 and HIV-2 among 12,287 women screened during the study period. From the sixty two (62) HIV-2 patients, the average age was 49.2 years (sex ratio was 0.65). The weight loss and diarrhea were the major clinical manifestations observed, respectively 54.8 and 25.8%. Fungi and herpes zoster (shingles) infections were reported as major opportunistic infections. Also, nearly half of the patients had more than 60 kg, less than 2% were in WHO stage IV and about 2/3 had a CD4 count bellow 250 cells mm(-3). AZT-3TC-IDV/LPV/R was the most prescribed combination. The gain in weight gain the Body Mass Index (BMI) improvement and the non-significant increase of the rate of CD4 between 1st (M1) and 24th month (M24) were observed after treatment with antiviral.
authors.forename: M
authors.initials: M
authors.lastname: Sanou
authors.forename: S T
authors.initials: ST
authors.lastname: Soubeiga
authors.forename: F
authors.initials: F
authors.lastname: Bationo
authors.forename: T R
authors.initials: TR
authors.lastname: Compaore
authors.forename: T M
authors.initials: TM
authors.lastname: Zohoncon
authors.forename: G N
authors.initials: GN
authors.lastname: Diatto
authors.forename: P
authors.initials: P
authors.lastname: Ouedraogo
authors.forename: V
authors.initials: V
authors.lastname: Pietra
authors.forename: B M
authors.initials: BM
authors.lastname: Nagalo
authors.forename: C
authors.initials: C
authors.lastname: Bisseye
authors.forename: R Ouedraogo
authors.initials: RO
authors.lastname: Traore
authors.forename: J
authors.initials: J
authors.lastname: Simpore
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D002050:Burkina Faso / Q000453:epidemiology; D018791:CD4 Lymphocyte Count; D018450:Disease Progression; D016903:Drug Monitoring / Q000379:methods; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology / Q000635:transmission / Q000821:virology; D015528:HIV Seroprevalence; D015497:HIV-1 / Q000187:drug effects / Q000276:immunology / Q000472:pathogenicity; D015498:HIV-2 / Q000187:drug effects* / Q000276:immunology / Q000472:pathogenicity; D006772:Hospitals, Military; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000453:epidemiology / Q000276:immunology / Q000821:virology; D011247:Pregnancy; D015995:Prevalence; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D015430:Weight Gain / Q000187:drug effects
chemical_list: D019380:Anti-HIV Agents